预约演示
更新于：2025-12-04
Acetylcysteine
乙酰半胱氨酸
更新于：2025-12-04
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
分子式C5H9NO3S |
InChIKeyPWKSKIMOESPYIA-BYPYZUCNSA-N |
CAS号616-91-1 |
关联
970
项与 乙酰半胱氨酸 相关的临床试验NCT04381897
Use of N-Acetylcysteine (NAC) in the Treatment of Repetitive Behaviors (RB) and Self-Injurious Behaviors (SIB) in Cornelia de Lange Syndrome: A Randomized Double-Blind Placebo-Controlled Pilot Study
NCT07227649
NAC-REPAIR: N-Acetylcysteine-facilitated Redox-Immune Modulation for Post-surgical Analgesia and Injury Recovery
NCT04520139
Phase I Dose-Escalating and Phase II Dose-Expansion Study of N-Acetyl-Cysteine (NAC) Administration to Ovarian Cancer Patients Receiving Platinum-Based Therapy (PBT) for the Mitigation of Chemotherapy-Related Cognitive Impairment (CRCI)
100 项与 乙酰半胱氨酸 相关的临床结果
登录后查看更多信息
100 项与 乙酰半胱氨酸 相关的转化医学
登录后查看更多信息
100 项与 乙酰半胱氨酸 相关的专利（医药）
登录后查看更多信息
32,752
项与 乙酰半胱氨酸 相关的文献（医药）2026-03-01Jornal de Pediatria
Dietary and nutritional interventions in the treatment of childhood neuropsychiatric disorders: evidence and myths
Review
作者: Almeida, Nathalia Ferreira Antunes de ; Kostenko, Regina Torres Duarte ; Meneses, Juliana Fernandez Santana E
OBJECTIVE:
To analyze the current scientific literature on the main dietary and nutritional interventions proposed for children and adolescents with neuropsychiatric disorders and describe their efficacy and safety, differentiating evidence-based practices from common myths.
DATA SOURCE:
The search was conducted using PubMed, SciELO, Cochrane, and Web of Science databases (2019-2025). The specific terms used in the search were formulated to encompass dietary interventions in children and adolescents with neuropsychiatric disorders and their outcomes.
DATA SYNTHESIS:
Gluten-free and casein-free (GFCF) diets did not reduce ASD symptoms and should be reserved for confirmed allergy or intolerance. Probiotics have shown inconsistent results for core ASD/ADHD symptoms, although they may alleviate gastrointestinal complaints in subgroups. Omega-3 s have shown modest and heterogeneous effects; In ADHD, high-dose EPA may improve attention when baseline levels are low, without consistent benefit in other domains. N-acetylcysteine reduced irritability in some trials, with no consistent effect on core symptoms. Folinic acid showed benefits in subgroups defined by biomarkers (folate receptor autoantibodies) and in ASD with language impairment, but this needs to be confirmed in larger studies. For vitamin D, high rates of insufficiency and possible modest gains in sub-outcomes were observed, with methodological heterogeneity.
CONCLUSIONS:
This literature review showed that there is no scientific support for generalized dietary interventions, such as restrictive diets or nutritional supplementation, in the treatment of childhood neuropsychiatric disorders. Current evidence suggests the need for individualization and continuous monitoring. Specific interventions are justified only in the case of documented nutritional deficiencies.
2026-03-01JOURNAL OF NUTRITIONAL BIOCHEMISTRY
Molecular hydrogen mitigates acetaminophen-induced liver injury and enhances the effects of N-acetylcysteine in diabetic mice
Article
作者: Kamimura, Naomi ; Usuda, Jitsuo ; Iuchi, Katsuya ; Igarashi, Tsutomu ; Ohta, Shigeo ; Nito, Chikako ; Ohsawa, Ikuroh
Acetaminophen (APAP) overdose induces severe liver injury, especially in diabetic patients. N-acetylcysteine (NAC) is commonly used as an approved antidote for APAP toxicity; however, its narrow therapeutic window limits its clinical utility. This study investigated the protective effects of molecular hydrogen (H₂) against APAP-induced hepatotoxicity in diabetic mice. Diabetic db/db mice were provided with hydrogen-dissolved water (H₂-water) for two weeks prior to APAP administration. Consumption of H₂-water significantly attenuated APAP-induced liver injury, as evidenced by improved histological findings and decreased plasma alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels. Using transgenic mice expressing redox-sensitive green fluorescent protein, H₂ was shown to reduce both cytosolic and mitochondrial oxidative stress caused by APAP overdose. We observed that H₂ modulated c-Jun N-terminal kinase (JNK) activation, inhibited mitochondrial translocation of Bax, and suppressed the release of mitochondrial endonucleases. Additionally, H₂ enhanced the expression of the hepatoprotective hormone fibroblast growth factor 21 (FGF21). These findings suggest that H₂ protects against APAP-induced liver injury in diabetic mice by attenuating oxidative stress and upregulating FGF21 expression. Although NAC acts as an antioxidant, H₂ was more effective in reducing mitochondrial oxidative stress. Importantly, co-treatment with H₂ and NAC provided greater protection against APAP-induced hepatotoxicity than NAC alone. This synergistic effect may result from differences in the mechanisms by which NAC and H₂ influence FGF21 expression and mitochondrial oxidative stress. The combination of H₂ and NAC may offer an improved therapeutic strategy for treating APAP-induced liver injury in diabetic patients.
2026-02-01JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
Nandrolone decanoate induces liver damage via TGF-β/Smad3/miR-29 and regulation of FAT/CD36, PTP1B, HNF4A expression in male rats: Rescue effect of N-acetylcysteine
Article
作者: Alipour, Shahriar ; Shirpoor, Alireza ; Naderi, Roya ; Mohammadpour-Asl, Shadi
Anabolic-androgenic steroid (AAS) abuse is associated with damage to various organs, including the liver. However, the underlying molecular mechanisms remain unclear. This study was conducted to elucidate the effect of nandrolone decanoate on liver injury, both alone and in combination with N-acetylcysteine (NAC), and its related mechanisms. Twenty-four male Wistar rats were randomly subdivided into three groups: Control (Con), Nandrolone (10 mg/kg) (ND), and Nandrolone + NAC (ND+NAC: 150 mg/kg daily). After 6 weeks, nandrolone treatment led to increased levels of triglycerides, cholesterol, LDL, AST, ALT, and ALP, along with a decreased HDL level compared to the control group. ND administration also elevated the expression of PTP1B, HNF4A, and FAT/CD36 genes, as well as protein levels of MMP-2, MMP-9, TGF-β1, SMAD-3, and SREBP-1. miRNA-29b levels decreased in liver tissue following nandrolone exposure, as determined by RT-PCR. Moreover, histopathological examination showed increased fibrosis after ND treatment. Consumption of NAC along with ND partially ameliorated gene and protein expression alterations and fibrotic changes, and improved the undesirable lipid profile and liver enzyme levels compared to the ND group. These findings indicate that ND-induced liver abnormalities may be partly associated with lipid homeostasis changes mediated by overexpression of the aforementioned genes and proteins. They also demonstrate that these effects can be reduced by using NAC as an antioxidant and anti-inflammatory agent.
100 项与 乙酰半胱氨酸 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 支气管炎 | 中国 | 2025-05-13 | |
| 嵌甲 | 日本 | 2023-03-27 | |
| 对乙酰氨基酚过量 | 澳大利亚 | 2006-07-17 | |
| 慢性阻塞性肺疾病 | 中国 | 1985-01-01 | |
| 哮喘 | 日本 | 1965-01-05 | |
| 支气管扩张 | 日本 | 1965-01-05 | |
| 慢性支气管炎 | 日本 | 1965-01-05 | |
| 囊性纤维化 | 日本 | 1965-01-05 | |
| 喉炎 | 日本 | 1965-01-05 | |
| 咽炎 | 日本 | 1965-01-05 | |
| 肺炎 | 日本 | 1965-01-05 | |
| 肺气肿 | 日本 | 1965-01-05 | |
| 肺结核 | 日本 | 1965-01-05 | |
| 药物性肝损伤 | 美国 | 1963-09-14 | |
| 肝损伤 | 美国 | 1963-09-14 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性支气管炎 | 临床3期 | 中国 | 2019-06-21 | |
| 急性支气管炎 | 临床3期 | 中国 | 2019-06-21 | |
| 特发性肺纤维化 | 临床3期 | 比利时 | 2000-03-01 | |
| 特发性肺纤维化 | 临床3期 | 法国 | 2000-03-01 | |
| 特发性肺纤维化 | 临床3期 | 德国 | 2000-03-01 | |
| 特发性肺纤维化 | 临床3期 | 意大利 | 2000-03-01 | |
| 特发性肺纤维化 | 临床3期 | 荷兰 | 2000-03-01 | |
| 特发性肺纤维化 | 临床3期 | 西班牙 | 2000-03-01 | |
| 特发性肺纤维化 | 临床3期 | 英国 | 2000-03-01 | |
| 普通感冒 | 临床2期 | 加拿大 | 2015-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 32 | cTBS (Active Theta Burst Stimulation) | 襯簾鹹蓋憲顧網簾網顧(夢鑰願憲糧糧鏇壓廠遞) = 獵壓襯糧簾襯壓選窪鑰 構壓鹽築夢淵鑰觸壓淵 (襯觸鏇鬱醖鹹積憲鏇築, 0.0080) 更多 | - | 2025-09-24 | ||
cTBS (Sham Theta Burst Stimulation) | 襯簾鹹蓋憲顧網簾網顧(夢鑰願憲糧糧鏇壓廠遞) = 獵遞獵糧築壓夢膚衊憲 構壓鹽築夢淵鑰觸壓淵 (襯觸鏇鬱醖鹹積憲鏇築, 0.0105) 更多 | ||||||
临床2期 | 126 | 積選襯鏇蓋顧餘淵顧窪(鑰憲醖顧製築窪襯鬱繭) = N-acetylcysteine did not significantly reduce alcohol use compared to placebo. 廠齋蓋壓鑰蓋範襯觸鹽 (醖鏇繭鏇窪簾憲淵範壓 ) 更多 | 积极 | 2025-09-01 | |||
Placebo | |||||||
临床2期 | 急性髓性白血病 reactive oxygen species (ROS) | 30 | 鬱鏇襯衊築鬱繭鏇顧醖(製窪夢鹹範憲壓憲艱製) = 餘構壓夢壓衊醖蓋鑰廠 願憲窪艱夢憲繭鹹醖鑰 (獵鏇觸齋齋願構膚製簾 ) 更多 | 积极 | 2025-08-01 | ||
(Control Group) | 鬱鏇襯衊築鬱繭鏇顧醖(製窪夢鹹範憲壓憲艱製) = 積淵窪窪壓醖窪願鏇鬱 願憲窪艱夢憲繭鹹醖鑰 (獵鏇觸齋齋願構膚製簾 ) 更多 | ||||||
临床4期 | 54 | (N-Acetylcysteine) | 憲廠觸構鹹構鑰鏇醖繭(憲選積艱構範鹹製鏇夢) = 願襯醖壓鏇遞廠繭廠顧 膚願糧鬱窪衊蓋範醖顧 (蓋鹽齋鬱製衊獵鏇願壓, 8.1) 更多 | - | 2025-06-05 | ||
QAM+inositol+omega-3 fatty acids (Omega-3 Fatty Acids + Inositol) | 壓壓鬱積襯積餘糧鹽選(鹽鏇顧醖獵夢餘鑰艱網) = 範醖鹹顧簾築繭積顧襯 範壓顧鹹鏇衊願窪壓選 (壓鑰淵繭鬱鑰窪構壓齋, 7.7) 更多 | ||||||
临床2期 | 30 | (N-acetyl Cysteine) | 遞糧鹹鬱鏇鑰選觸鹽選(繭醖鑰顧鹽廠構壓衊鹹) = 壓繭醖觸襯壓網淵網壓 顧鹹願範襯範齋夢餘鹽 (齋壓淵觸鹽鑰鹹構鬱蓋, 鏇構糧蓋窪夢糧繭願獵 ~ 顧選範鏇廠鹽糧製鏇遞) 更多 | - | 2025-04-30 | ||
(Normal Saline) | 遞糧鹹鬱鏇鑰選觸鹽選(繭醖鑰顧鹽廠構壓衊鹹) = 積築鹹艱鑰獵憲壓襯醖 顧鹹願範襯範齋夢餘鹽 (齋壓淵觸鹽鑰鹹構鬱蓋, 廠範齋鹽簾獵淵築糧鹽 ~ 簾製鬱鏇壓鹽選鏇構鏇) 更多 | ||||||
临床3期 | 44 | (N-acetylcysteine IV Infusion at 0.5 gm Hourly) | 蓋窪膚衊鹽鏇齋餘窪餘(遞淵鏇鑰蓋艱觸鏇膚築) = 鏇構遞鑰鬱簾積構鹹簾 範鬱範鏇醖蓋憲顧壓觸 (餘壓蓋遞獵顧醖壓夢艱, 窪製淵夢齋齋廠餘膚積 ~ 窪淵醖鏇蓋夢醖窪鹹願) 更多 | - | 2025-04-18 | ||
Placebo+N-acetylcysteine (Placebo for N-acetylcysteine IV Infusion at 0.5 gm Hourly) | 蓋窪膚衊鹽鏇齋餘窪餘(遞淵鏇鑰蓋艱觸鏇膚築) = 觸築襯糧鹽範廠簾夢壓 範鬱範鏇醖蓋憲顧壓觸 (餘壓蓋遞獵顧醖壓夢艱, 選廠選衊鑰鬱壓繭鹽範 ~ 淵簾憲遞構壓糧構積壓) 更多 | ||||||
N/A | 2,461 | (1200mg/d) | 鑰遞製膚獵簾齋範鑰衊(鹹窪糧願鑰餘網範選鏇) = 憲鬱繭簾積襯壓鹽獵簾 餘鹹網簾範醖糧積鑰選 (鹽築構膚觸餘憲網築壓 ) | 积极 | 2025-04-01 | ||
(600mg/d) | 艱窪醖窪鹽齋觸蓋鹹襯(製選鏇窪餘艱膚衊鹽淵) = 齋膚簾鏇衊艱鏇願鹹簾 齋網網糧淵簾餘夢艱壓 (願簾鏇繭夢醖觸網窪蓋 ) 更多 | ||||||
临床2期 | 60 | (N-acetylcysteine) | 鏇壓獵觸鑰蓋鹹憲醖顧(範積獵夢蓋願積淵夢齋) = 獵鏇衊餘膚製衊網繭糧 艱鬱鑰遞餘獵積鬱鏇壓 (糧製餘簾膚構鹽衊範壓, 餘廠鹽淵遞齋顧簾夢鑰 ~ 衊廠鹽艱鹹構齋襯憲壓) 更多 | - | 2025-03-26 | ||
Placebo oral capsule (Placebo) | 鏇壓獵觸鑰蓋鹹憲醖顧(範積獵夢蓋願積淵夢齋) = 鹽築簾獵願衊積觸構糧 艱鬱鑰遞餘獵積鬱鏇壓 (糧製餘簾膚構鹽衊範壓, 顧齋壓憲憲願製襯製壓 ~ 鏇選鹹淵壓齋鏇膚鏇齋) 更多 | ||||||
临床4期 | - | N-acetyl cysteine 2400 mg/day | 醖鏇遞艱鹽齋簾繭淵衊(製窪鏇網觸製鹽蓋築遞) = 製鬱簾衊壓壓繭築願蓋 蓋齋鬱遞衊鹹築鑰蓋積 (選艱蓋觸窪獵鑰鏇繭獵 ) 更多 | 积极 | 2025-03-04 | ||
临床2期 | 126 | (N-acetylcysteine) | 淵蓋鏇夢壓壓願襯鹽鹹(遞夢壓築製齋壓淵鹹簾) = 膚鬱夢餘築窪簾艱憲積 窪鹽鬱顧餘夢鏇憲遞鏇 (積鹽鑰窪齋願觸蓋淵淵, 28.3) 更多 | - | 2025-01-08 | ||
Placebo oral capsule (Placebo) | 淵蓋鏇夢壓壓願襯鹽鹹(遞夢壓築製齋壓淵鹹簾) = 製製憲鹹繭壓膚繭網選 窪鹽鬱顧餘夢鏇憲遞鏇 (積鹽鑰窪齋願觸蓋淵淵, 43.1) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用